nilvadipine has been researched along with Collagen Diseases in 1 studies
Collagen Diseases: Historically, a heterogeneous group of acute and chronic diseases, including rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis, dermatomyositis, etc. This classification was based on the notion that collagen was equivalent to connective tissue, but with the present recognition of the different types of collagen and the aggregates derived from them as distinct entities, the term collagen diseases now pertains exclusively to those inherited conditions in which the primary defect is at the gene level and affects collagen biosynthesis, post-translational modification, or extracellular processing directly. (From Cecil Textbook of Medicine, 19th ed, p1494)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kagawa, H | 1 |
Nomura, S | 1 |
Ozaki, Y | 1 |
Nagahama, M | 1 |
Fukuhara, S | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease[NCT02017340] | Phase 3 | 511 participants (Actual) | Interventional | 2013-04-24 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 other study available for nilvadipine and Collagen Diseases
Article | Year |
---|---|
Effects of nilvadipine on cytokine-levels and soluble factors in collagen disease complicated with essential hypertension.
Topics: Adult; Aged; Blood Pressure; Calcium Channel Blockers; CD4-CD8 Ratio; Collagen Diseases; Cytokines; | 1999 |